Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas
The microRNA encoding genes miR-34a and miR-34b/c represent direct p53 target genes and possess tumor suppressive properties as they mediate apoptosis, cell cycle arrest, and senescence. We previously reported that the miR-34a gene is subject to epigenetic inactivation by CpG methylation of its prom...
Saved in:
| Published in: | Virchows Archiv : an international journal of pathology Vol. 458; no. 3; pp. 313 - 322 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Berlin/Heidelberg
Springer-Verlag
01.03.2011
Springer Springer Nature B.V |
| Subjects: | |
| ISSN: | 0945-6317, 1432-2307, 1432-2307 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The microRNA encoding genes
miR-34a
and
miR-34b/c
represent direct p53 target genes and possess tumor suppressive properties as they mediate apoptosis, cell cycle arrest, and senescence. We previously reported that the
miR-34a
gene is subject to epigenetic inactivation by CpG methylation of its promoter region in primary prostate cancer and melanomas, and in 110 different cancer cell lines of diverse origin. Here we analyzed the methylation status of
miR-34a
and
miR-34b/c
in additional primary tumors of divergent sites. We found methylation of
miR-34a
or
miR-34b/c
in formalin-fixed, paraffin-embedded (FFPE) tumor samples from 178 patients with the following frequencies: colorectal cancer (74%
miR-34a
, 99%
miR-34b/c
;
n
= 114), pancreatic cancer (64%, 100%;
n
= 11), mammary cancer (60%, 90%;
n
= 10), ovarian cancer (62%, 69%;
n
= 13), urothelial cancer (71%, 57%;
n
= 7), and renal cell cancer (58%, 100%;
n
= 12). Furthermore, soft tissue sarcomas showed methylation of
miR-34
gene promoters in FFPE samples (64%, 45%;
n
= 11), in explanted, cultured cells (53%, 40%;
n
= 40), and in frozen tissue samples (75%, 75%,
n
= 8). In the colorectal cancer samples a statistically significant correlation of
miR-34a
methylation and the absence of p53 mutation was detected. With the exception of sarcoma cell lines, the inactivation of
miR-34a
and
miR-34b/c
was concomitant in most cases. These results show that
miR-34
inactivation is a common event in tumor formation, and suggest that CpG methylation of
miR-34a
and
miR-34-b/c
may have diagnostic value. The mutual exclusiveness of
miR-34a
methylation and p53 mutation indicates that
miR-34a
inactivation may substitute for loss of p53 function in cancer. |
|---|---|
| AbstractList | The microRNA encoding genes miR-34a and miR-34b/c represent direct p53 target genes and possess tumor suppressive properties as they mediate apoptosis, cell cycle arrest, and senescence. We previously reported that the miR-34a gene is subject to epigenetic inactivation by CpG methylation of its promoter region in primary prostate cancer and melanomas, and in 110 different cancer cell lines of diverse origin. Here we analyzed the methylation status of miR-34a and miR-34b/c in additional primary tumors of divergent sites. We found methylation of miR-34a or miR-34b/c in formalin-fixed, paraffin-embedded (FFPE) tumor samples from 178 patients with the following frequencies: colorectal cancer (74% miR-34a, 99% miR-34b/c; n=114), pancreatic cancer (64%, 100%; n=11), mammary cancer (60%, 90%; n=10), ovarian cancer (62%, 69%; n=13), urothelial cancer (71%, 57%; n=7), and renal cell cancer (58%, 100%; n=12). Furthermore, soft tissue sarcomas showed methylation of miR-34 gene promoters in FFPE samples (64%, 45%; n=11), in explanted, cultured cells (53%, 40%; n=40), and in frozen tissue samples (75%, 75%, n=8). In the colorectal cancer samples a statistically significant correlation of miR-34a methylation and the absence of p53 mutation was detected. With the exception of sarcoma cell lines, the inactivation of miR-34a and miR-34b/c was concomitant in most cases. These results show that miR-34 inactivation is a common event in tumor formation, and suggest that CpG methylation of miR-34a and miR-34-b/c may have diagnostic value. The mutual exclusiveness of miR-34a methylation and p53 mutation indicates that miR-34a inactivation may substitute for loss of p53 function in cancer. The microRNA encoding genes miR-34a and miR-34b/c represent direct p53 target genes and possess tumor suppressive properties as they mediate apoptosis, cell cycle arrest, and senescence. We previously reported that the miR-34a gene is subject to epigenetic inactivation by CpG methylation of its promoter region in primary prostate cancer and melanomas, and in 110 different cancer cell lines of diverse origin. Here we analyzed the methylation status of miR-34a and miR-34b/c in additional primary tumors of divergent sites. We found methylation of miR-34a or miR-34b/c in formalin-fixed, paraffin-embedded (FFPE) tumor samples from 178 patients with the following frequencies: colorectal cancer (74% miR-34a, 99% miR-34b/c; n=114), pancreatic cancer (64%, 100%; n=11), mammary cancer (60%, 90%; n=10), ovarian cancer (62%, 69%; n=13), urothelial cancer (71%, 57%; n=7), and renal cell cancer (58%, 100%; n=12). Furthermore, soft tissue sarcomas showed methylation of miR-34 gene promoters in FFPE samples (64%, 45%; n=11), in explanted, cultured cells (53%, 40%; n=40), and in frozen tissue samples (75%, 75%, n=8). In the colorectal cancer samples a statistically significant correlation of miR-34a methylation and the absence of p53 mutation was detected. With the exception of sarcoma cell lines, the inactivation of miR-34a and miR-34b/c was concomitant in most cases. These results show that miR-34 inactivation is a common event in tumor formation, and suggest that CpG methylation of miR-34a and miR-34-b/c may have diagnostic value. The mutual exclusiveness of miR-34a methylation and p53 mutation indicates that miR-34a inactivation may substitute for loss of p53 function in cancer.[PUBLICATION ABSTRACT] The microRNA encoding genes miR-34a and miR-34b/c represent direct p53 target genes and possess tumor suppressive properties as they mediate apoptosis, cell cycle arrest, and senescence. We previously reported that the miR-34a gene is subject to epigenetic inactivation by CpG methylation of its promoter region in primary prostate cancer and melanomas, and in 110 different cancer cell lines of diverse origin. Here we analyzed the methylation status of miR-34a and miR-34b/c in additional primary tumors of divergent sites. We found methylation of miR-34a or miR-34b/c in formalin-fixed, paraffin-embedded (FFPE) tumor samples from 178 patients with the following frequencies: colorectal cancer (74% miR-34a, 99% miR-34b/c; n = 114), pancreatic cancer (64%, 100%; n = 11), mammary cancer (60%, 90%; n = 10), ovarian cancer (62%, 69%; n = 13), urothelial cancer (71%, 57%; n = 7), and renal cell cancer (58%, 100%; n = 12). Furthermore, soft tissue sarcomas showed methylation of miR-34 gene promoters in FFPE samples (64%, 45%; n = 11), in explanted, cultured cells (53%, 40%; n = 40), and in frozen tissue samples (75%, 75%, n = 8). In the colorectal cancer samples a statistically significant correlation of miR-34a methylation and the absence of p53 mutation was detected. With the exception of sarcoma cell lines, the inactivation of miR-34a and miR-34b/c was concomitant in most cases. These results show that miR-34 inactivation is a common event in tumor formation, and suggest that CpG methylation of miR-34a and miR-34-b/c may have diagnostic value. The mutual exclusiveness of miR-34a methylation and p53 mutation indicates that miR-34a inactivation may substitute for loss of p53 function in cancer.The microRNA encoding genes miR-34a and miR-34b/c represent direct p53 target genes and possess tumor suppressive properties as they mediate apoptosis, cell cycle arrest, and senescence. We previously reported that the miR-34a gene is subject to epigenetic inactivation by CpG methylation of its promoter region in primary prostate cancer and melanomas, and in 110 different cancer cell lines of diverse origin. Here we analyzed the methylation status of miR-34a and miR-34b/c in additional primary tumors of divergent sites. We found methylation of miR-34a or miR-34b/c in formalin-fixed, paraffin-embedded (FFPE) tumor samples from 178 patients with the following frequencies: colorectal cancer (74% miR-34a, 99% miR-34b/c; n = 114), pancreatic cancer (64%, 100%; n = 11), mammary cancer (60%, 90%; n = 10), ovarian cancer (62%, 69%; n = 13), urothelial cancer (71%, 57%; n = 7), and renal cell cancer (58%, 100%; n = 12). Furthermore, soft tissue sarcomas showed methylation of miR-34 gene promoters in FFPE samples (64%, 45%; n = 11), in explanted, cultured cells (53%, 40%; n = 40), and in frozen tissue samples (75%, 75%, n = 8). In the colorectal cancer samples a statistically significant correlation of miR-34a methylation and the absence of p53 mutation was detected. With the exception of sarcoma cell lines, the inactivation of miR-34a and miR-34b/c was concomitant in most cases. These results show that miR-34 inactivation is a common event in tumor formation, and suggest that CpG methylation of miR-34a and miR-34-b/c may have diagnostic value. The mutual exclusiveness of miR-34a methylation and p53 mutation indicates that miR-34a inactivation may substitute for loss of p53 function in cancer. The microRNA encoding genes miR-34a and miR-34b/c represent direct p53 target genes and possess tumor suppressive properties as they mediate apoptosis, cell cycle arrest, and senescence. We previously reported that the miR-34a gene is subject to epigenetic inactivation by CpG methylation of its promoter region in primary prostate cancer and melanomas, and in 110 different cancer cell lines of diverse origin. Here we analyzed the methylation status of miR-34a and miR-34b/c in additional primary tumors of divergent sites. We found methylation of miR-34a or miR-34b/c in formalin-fixed, paraffin-embedded (FFPE) tumor samples from 178 patients with the following frequencies: colorectal cancer (74% miR-34a , 99% miR-34b/c ; n = 114), pancreatic cancer (64%, 100%; n = 11), mammary cancer (60%, 90%; n = 10), ovarian cancer (62%, 69%; n = 13), urothelial cancer (71%, 57%; n = 7), and renal cell cancer (58%, 100%; n = 12). Furthermore, soft tissue sarcomas showed methylation of miR-34 gene promoters in FFPE samples (64%, 45%; n = 11), in explanted, cultured cells (53%, 40%; n = 40), and in frozen tissue samples (75%, 75%, n = 8). In the colorectal cancer samples a statistically significant correlation of miR-34a methylation and the absence of p53 mutation was detected. With the exception of sarcoma cell lines, the inactivation of miR-34a and miR-34b/c was concomitant in most cases. These results show that miR-34 inactivation is a common event in tumor formation, and suggest that CpG methylation of miR-34a and miR-34-b/c may have diagnostic value. The mutual exclusiveness of miR-34a methylation and p53 mutation indicates that miR-34a inactivation may substitute for loss of p53 function in cancer. |
| Author | Grüner, Martha Liffers, Sven-Thorsten Hauk, Jennifer Tannapfel, Andrea Vogt, Markus Verdoodt, Berlinda Munding, Johanna Hermeking, Heiko Steinstraesser, Lars |
| Author_xml | – sequence: 1 givenname: Markus surname: Vogt fullname: Vogt, Markus organization: Institute of Pathology, Ruhr-University-Bochum – sequence: 2 givenname: Johanna surname: Munding fullname: Munding, Johanna organization: Institute of Pathology, Ruhr-University-Bochum – sequence: 3 givenname: Martha surname: Grüner fullname: Grüner, Martha organization: Institute of Pathology, Ruhr-University-Bochum – sequence: 4 givenname: Sven-Thorsten surname: Liffers fullname: Liffers, Sven-Thorsten organization: Institute of Pathology, Ruhr-University-Bochum – sequence: 5 givenname: Berlinda surname: Verdoodt fullname: Verdoodt, Berlinda organization: Institute of Pathology, Ruhr-University-Bochum – sequence: 6 givenname: Jennifer surname: Hauk fullname: Hauk, Jennifer organization: Department of Plastic and Reconstructive Surgery, Department of Hand Surgery, Soft Tissue Tumour Reference Centre, BG University Hospital Bergmannsheil, Ruhr University Bochum – sequence: 7 givenname: Lars surname: Steinstraesser fullname: Steinstraesser, Lars organization: Department of Plastic and Reconstructive Surgery, Department of Hand Surgery, Soft Tissue Tumour Reference Centre, BG University Hospital Bergmannsheil, Ruhr University Bochum – sequence: 8 givenname: Andrea surname: Tannapfel fullname: Tannapfel, Andrea organization: Institute of Pathology, Ruhr-University-Bochum – sequence: 9 givenname: Heiko surname: Hermeking fullname: Hermeking, Heiko email: heiko.hermeking@med.uni-muenchen.de organization: Institute of Pathology, Ruhr-University-Bochum, Experimental and Molecular Pathology, Institute of Pathology, Ludwig-Maximilians-University Munich |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23947296$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21225432$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kt1qFDEUx4NU7Lb6AN5IEEQvdmw-JpnJZVlsFQqC6PVw9mzGpswka5Ip7KP5dmZ2VwsFe5Oc8P-dk_N1Rk588JaQ15x95Iw1F4mxWrQV46ziTLJKPSMLXktRCcmaE7JgplaVlrw5JWcp3TEmeMv1C3IquBCqgAvy-yraX5P1mWLwGEaXodjOA2Z3D9kFT0NPR_etkjVQ8Jujvb5Aut7R1faajjbf7oYD63yJM4RoMcOwpFvwGG2RcElHGEeIuyUN9xAd-CWdYsi3dnAzOUeO1sNA0Q7lgIjOhxHSXkmhzzS7lCZLU5Fm4SV53sOQ7KvjfU5-XH36vvpc3Xy9_rK6vKmwNiZX2K9BoKmtUYjYa4VirRUYrQVrWuw3DYBppDKMt6ChiJuNFo3BVgnRYC3PyftD3G0MpVMpd6NLc5LgbZhS1yppjJR8Jj88SfJat1IJplRB3z5C78IUS_n7eIoprk2B3hyhaT3aTbeNbu5g93d6BXh3BCAhDH0s7XbpgZOmboTRheMHDmNIKdr-H8JZN29Sd9ikju3fknVzhs0jHyy7MQ85R3DDk57i4JnKL_6njQ-1_d_pDxz03Jc |
| CitedBy_id | crossref_primary_10_1016_j_jbior_2019_04_004 crossref_primary_10_1053_j_gastro_2015_07_011 crossref_primary_10_1038_bjc_2016_454 crossref_primary_10_1016_j_bcp_2011_12_026 crossref_primary_10_1016_j_molonc_2012_07_007 crossref_primary_10_1016_j_bbagen_2012_10_014 crossref_primary_10_1016_j_omton_2024_200765 crossref_primary_10_1093_carcin_bgr286 crossref_primary_10_2217_epi_12_39 crossref_primary_10_1261_rna_052571_115 crossref_primary_10_1007_s12035_014_8803_9 crossref_primary_10_1158_1541_7786_MCR_12_0274 crossref_primary_10_3892_ol_2018_9575 crossref_primary_10_1038_s41418_023_01193_2 crossref_primary_10_1016_j_jpedsurg_2016_02_091 crossref_primary_10_1186_1476_4598_13_115 crossref_primary_10_1016_j_cll_2018_02_003 crossref_primary_10_3892_or_2014_3142 crossref_primary_10_1134_S1022795413030034 crossref_primary_10_1074_jbc_AC119_010419 crossref_primary_10_1097_MD_0000000000025827 crossref_primary_10_1002_ijc_27345 crossref_primary_10_1007_s11888_011_0116_z crossref_primary_10_1016_j_gene_2016_12_018 crossref_primary_10_1002_jcp_27990 crossref_primary_10_3892_ijmm_2018_4003 crossref_primary_10_1038_s41418_023_01178_1 crossref_primary_10_1371_journal_pgen_1002363 crossref_primary_10_1158_1078_0432_CCR_12_2952 crossref_primary_10_1186_s13046_019_1059_5 crossref_primary_10_1002_jcp_28160 crossref_primary_10_3233_CBM_170289 crossref_primary_10_1038_s41598_020_66561_1 crossref_primary_10_3892_ijo_2024_5650 crossref_primary_10_1016_j_semcancer_2020_05_017 crossref_primary_10_1016_j_cll_2013_08_001 crossref_primary_10_1016_j_molonc_2016_03_008 crossref_primary_10_1134_S1022795418070086 crossref_primary_10_1038_bjc_2013_449 crossref_primary_10_1002_ijc_29413 crossref_primary_10_1158_0008_5472_CAN_16_2183 crossref_primary_10_1016_j_addr_2014_10_020 crossref_primary_10_1002_gcc_22332 crossref_primary_10_4161_epi_25927 crossref_primary_10_1007_s00204_016_1815_7 crossref_primary_10_4161_cc_25135 crossref_primary_10_1158_1078_0432_CCR_13_0736 crossref_primary_10_1038_s41417_020_00210_7 crossref_primary_10_2217_epi_11_93 crossref_primary_10_3748_wjg_v20_i32_11199 crossref_primary_10_1038_cgt_2016_77 crossref_primary_10_1038_bjc_2012_537 crossref_primary_10_1289_ehp_1408459 crossref_primary_10_3390_ijms19092791 crossref_primary_10_1038_s41419_018_0777_5 crossref_primary_10_3892_ol_2020_11837 crossref_primary_10_1016_j_yexmp_2015_06_014 crossref_primary_10_1007_s11033_012_2063_4 crossref_primary_10_1007_s00438_014_0960_z crossref_primary_10_1016_j_acthis_2020_151576 crossref_primary_10_1016_j_canlet_2014_05_022 crossref_primary_10_1186_s13045_016_0323_9 crossref_primary_10_1038_ki_2011_448 crossref_primary_10_1016_j_jgg_2013_03_002 crossref_primary_10_1016_j_jgg_2018_03_001 crossref_primary_10_1016_j_phrs_2013_03_006 crossref_primary_10_3389_fgene_2024_1461404 crossref_primary_10_1002_jcp_26095 crossref_primary_10_1016_j_ajpath_2014_10_006 crossref_primary_10_3390_cancers13061333 crossref_primary_10_1111_bju_12551 crossref_primary_10_1007_s13277_014_2861_5 crossref_primary_10_1186_1756_9966_33_20 crossref_primary_10_1007_s40291_019_00381_6 crossref_primary_10_1073_pnas_1703029115 crossref_primary_10_1016_j_gene_2014_03_059 crossref_primary_10_1016_j_ajpath_2017_06_014 crossref_primary_10_1038_nrc3265 crossref_primary_10_1007_s11033_015_3860_3 crossref_primary_10_3390_pharmaceutics17081084 crossref_primary_10_1080_14737159_2017_1337511 crossref_primary_10_1158_1940_6207_CAPR_14_0357 crossref_primary_10_1007_s00018_021_03979_4 crossref_primary_10_1158_1078_0432_CCR_12_1703 crossref_primary_10_3892_ol_2013_1428 crossref_primary_10_1007_s00432_014_1690_7 crossref_primary_10_1016_j_yexmp_2014_08_002 crossref_primary_10_1007_s40495_015_0016_z crossref_primary_10_1038_s41417_020_00224_1 crossref_primary_10_1186_s12885_016_2253_x crossref_primary_10_2217_fon_13_259 crossref_primary_10_1134_S1022795415050026 crossref_primary_10_1016_j_jacc_2012_02_033 crossref_primary_10_1038_s41467_021_21162_y crossref_primary_10_1007_s13277_014_2572_y crossref_primary_10_1007_s40495_014_0008_4 crossref_primary_10_1053_j_gastro_2012_09_032 crossref_primary_10_1158_0008_5472_CAN_15_2321 crossref_primary_10_1586_erm_13_38 crossref_primary_10_1038_nrc3447 crossref_primary_10_1016_j_ymeth_2012_09_002 crossref_primary_10_1158_0008_5472_CAN_12_0803 crossref_primary_10_3892_ol_2019_10092 crossref_primary_10_1016_j_clinre_2014_10_007 crossref_primary_10_3389_fgene_2019_00320 crossref_primary_10_1111_jcmm_12368 crossref_primary_10_1038_cddis_2017_495 crossref_primary_10_1016_j_cllc_2016_06_005 crossref_primary_10_1016_j_euf_2015_11_006 crossref_primary_10_1038_ncb3611 crossref_primary_10_1155_2014_678401 crossref_primary_10_1371_journal_pone_0117107 crossref_primary_10_3390_ijms19020459 crossref_primary_10_1155_2013_719202 crossref_primary_10_3389_fbioe_2022_911769 crossref_primary_10_1016_j_neulet_2017_04_061 crossref_primary_10_3892_mmr_2018_9182 crossref_primary_10_1007_s10552_013_0187_z crossref_primary_10_1371_journal_pone_0124899 crossref_primary_10_1007_s10534_015_9872_6 crossref_primary_10_1016_j_critrevonc_2018_09_006 crossref_primary_10_1016_j_stem_2013_04_018 crossref_primary_10_1016_j_ijbiomac_2017_10_154 crossref_primary_10_1158_1541_7786_MCR_14_0424 crossref_primary_10_1016_j_gene_2023_148069 crossref_primary_10_2147_OTT_S234549 crossref_primary_10_1016_j_phrs_2021_105611 crossref_primary_10_1134_S0026893318020140 crossref_primary_10_3389_fonc_2022_960269 crossref_primary_10_1002_lary_25475 crossref_primary_10_1007_s00595_012_0392_5 crossref_primary_10_1097_MD_0000000000005050 crossref_primary_10_1097_MD_0000000000023716 crossref_primary_10_1016_j_snb_2021_129624 crossref_primary_10_3892_etm_2012_585 crossref_primary_10_1007_s00441_014_1793_0 crossref_primary_10_1074_jbc_M111_280768 crossref_primary_10_1186_s12951_024_02559_5 crossref_primary_10_1038_srep09742 crossref_primary_10_1586_erm_12_39 crossref_primary_10_1007_s00296_015_3260_y crossref_primary_10_1007_s12032_014_0894_7 crossref_primary_10_1530_REP_14_0239 crossref_primary_10_3390_cancers5020676 crossref_primary_10_1016_j_yexmp_2017_05_012 crossref_primary_10_3390_ijms20184600 crossref_primary_10_1016_j_bbcan_2012_01_004 crossref_primary_10_1038_clpt_2012_192 crossref_primary_10_1016_j_bbcan_2016_01_001 crossref_primary_10_1007_s12253_020_00842_y crossref_primary_10_1093_humupd_dmr041 crossref_primary_10_1155_2022_7214904 crossref_primary_10_1007_s00210_024_03594_7 crossref_primary_10_2217_epi_15_6 crossref_primary_10_1093_mutage_geu001 crossref_primary_10_1007_s00018_015_2020_1 crossref_primary_10_1002_path_4037 crossref_primary_10_1007_s11033_013_2998_0 crossref_primary_10_1053_j_gastro_2018_08_011 crossref_primary_10_3390_ijms25084157 crossref_primary_10_1134_S0006297915020029 crossref_primary_10_1016_j_ajpath_2018_10_005 crossref_primary_10_3748_wjg_v20_i45_17011 crossref_primary_10_1002_jcp_26116 crossref_primary_10_1158_0008_5472_CAN_12_2230 crossref_primary_10_1016_j_biopha_2013_10_002 crossref_primary_10_3892_ol_2016_5033 crossref_primary_10_1038_s41420_022_01054_w crossref_primary_10_1002_mc_22296 crossref_primary_10_1016_j_clinbiochem_2013_03_019 crossref_primary_10_1371_journal_pone_0135991 crossref_primary_10_3390_cancers16091681 crossref_primary_10_1016_j_ejca_2016_12_018 crossref_primary_10_1371_journal_pone_0080570 crossref_primary_10_1038_s41388_018_0390_1 crossref_primary_10_1155_2015_892903 crossref_primary_10_1016_j_canep_2014_06_005 crossref_primary_10_1080_00365521_2017_1301989 crossref_primary_10_1016_j_bbagrm_2014_04_003 crossref_primary_10_1038_s41585_018_0023_z crossref_primary_10_1038_onc_2012_311 crossref_primary_10_7717_peerj_15777 crossref_primary_10_3390_ph6101195 crossref_primary_10_1186_s12885_017_3638_1 crossref_primary_10_1016_j_arcmed_2019_05_008 crossref_primary_10_3390_ijms232012381 crossref_primary_10_1016_j_yexmp_2015_03_017 crossref_primary_10_1016_j_cancergen_2012_03_001 crossref_primary_10_1016_j_toxlet_2019_11_012 crossref_primary_10_3390_cancers13164072 crossref_primary_10_1186_1756_8722_5_58 crossref_primary_10_3390_antiox12050997 crossref_primary_10_1093_bib_bbac390 crossref_primary_10_1517_14728222_2016_1114102 crossref_primary_10_4161_epi_19464 crossref_primary_10_1007_s12032_012_0413_7 crossref_primary_10_3892_ol_2021_13066 crossref_primary_10_1016_j_jpedsurg_2016_09_070 crossref_primary_10_1016_j_neurobiolaging_2013_10_082 crossref_primary_10_1186_s12885_016_2135_2 crossref_primary_10_1016_j_fertnstert_2013_09_009 crossref_primary_10_1016_j_genrep_2021_101416 crossref_primary_10_1038_nrurol_2012_104 crossref_primary_10_3390_biomedicines3010032 |
| Cites_doi | 10.1126/science.1140735 10.1002/ijc.25269 10.1146/annurev.med.59.053006.104707 10.1093/carcin/bgq033 10.1038/nature05939 10.1073/pnas.0910015107 10.1038/cdd.2009.109 10.1200/JCO.2005.00.471 10.1073/pnas.0803055105 10.1016/j.cell.2007.01.029 10.1158/0008-5472.CAN-08-2148 10.1016/j.molcel.2007.05.010 10.1158/0008-5472.CAN-10-0655 10.4161/cc.6.13.4436 10.1002/humu.10175 10.1158/0008-5472.CAN-09-0529 10.1200/JCO.2005.07.021 10.1158/1078-0432.CCR-09-2642 10.1016/j.canlet.2008.09.035 10.1158/0008-5472.CAN-08-0325 10.1371/journal.pone.0006816 10.4161/cc.7.16.6533 10.1016/j.molcel.2007.05.017 10.1038/nrg2634 10.1158/0008-5472.CAN-07-1585 10.1038/cdd.2009.56 10.1073/pnas.0707351104 10.1016/j.cub.2007.06.068 10.1038/sj.onc.1210293 10.1073/pnas.93.18.9821 10.1093/carcin/bgp219 10.1038/nrc1045 10.1016/j.ccr.2007.10.028 10.1038/nrg816 |
| ContentType | Journal Article |
| Copyright | Springer-Verlag 2011 2015 INIST-CNRS |
| Copyright_xml | – notice: Springer-Verlag 2011 – notice: 2015 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7RV 7T5 7T7 7TM 7TO 7U7 7U9 7X7 7XB 88A 88E 8AO 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB0 LK8 M0S M1P M7P NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1007/s00428-010-1030-5 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences ProQuest Health & Medical Collection PML(ProQuest Medical Library) Biological Science Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts Toxicology Abstracts ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Nucleic Acids Abstracts ProQuest Central Student MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1432-2307 |
| EndPage | 322 |
| ExternalDocumentID | 2274987111 21225432 23947296 10_1007_s00428_010_1030_5 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .55 .86 .GJ .VR 04C 06C 06D 0R~ 0VY 1N0 2.D 203 28- 29Q 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3O- 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67Z 6NX 78A 7RV 7X7 88A 88E 8AO 8FE 8FH 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABOCM ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEUYN AEVLU AEXYK AFBBN AFEXP AFFNX AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBNVY BBWZM BDATZ BENPR BGNMA BHPHI BKEYQ BMSDO BPHCQ BSONS BVXVI CAG CCPQU COF CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBLON EBS EIHBH EIOEI EJD EMOBN EN4 ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HCIFZ HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LK8 LLZTM M0L M1P M4Y M7P MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RIG RNI RNS RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOW X7M YLTOR Z45 Z7U Z81 Z82 Z87 Z8O Z8U Z8V Z91 ZGI ZMTXR ZOVNA ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PQGLB IQODW CGR CUY CVF ECM EIF NPM 7T5 7T7 7TM 7TO 7U7 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. P64 PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c499t-cfba2c94e95cccf65c2b65a9662078cfd7aa97359018a6a2b6dd6279c85227c43 |
| IEDL.DBID | 7RV |
| ISICitedReferencesCount | 269 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000288679000007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0945-6317 1432-2307 |
| IngestDate | Fri Sep 05 11:35:17 EDT 2025 Fri Sep 05 13:24:25 EDT 2025 Tue Nov 04 21:46:43 EST 2025 Wed Feb 19 01:48:25 EST 2025 Mon Jul 21 09:12:10 EDT 2025 Tue Nov 18 22:23:43 EST 2025 Sat Nov 29 04:13:39 EST 2025 Fri Feb 21 02:35:32 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | CpG methylation family p53 Cancer Epigenetic inactivation Ovary carcinoma miR-34a Ovary cancer Transitional cell carcinoma Inactivation TP53 Gene GC rich sequence Family environment Grawitz tumor Colon Mammary gland Pancreas Tumor suppressor gene Kidney disease Urinary system disease miR-34 family Nucleotide sequence Digestive system Family study Gut Soft tissue sarcoma Malignant tumor Female genital diseases Ovarian diseases miR-34b/c Kidney cancer Rectum Breast Frequency Methylation |
| Language | English |
| License | http://www.springer.com/tdm CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c499t-cfba2c94e95cccf65c2b65a9662078cfd7aa97359018a6a2b6dd6279c85227c43 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| PMID | 21225432 |
| PQID | 853505169 |
| PQPubID | 54092 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_853993314 proquest_miscellaneous_1468352055 proquest_journals_853505169 pubmed_primary_21225432 pascalfrancis_primary_23947296 crossref_primary_10_1007_s00428_010_1030_5 crossref_citationtrail_10_1007_s00428_010_1030_5 springer_journals_10_1007_s00428_010_1030_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-03-01 |
| PublicationDateYYYYMMDD | 2011-03-01 |
| PublicationDate_xml | – month: 03 year: 2011 text: 2011-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Heidelberg – name: Germany |
| PublicationSubtitle | The European Journal of Pathology |
| PublicationTitle | Virchows Archiv : an international journal of pathology |
| PublicationTitleAbbrev | Virchows Arch |
| PublicationTitleAlternate | Virchows Arch |
| PublicationYear | 2011 |
| Publisher | Springer-Verlag Springer Springer Nature B.V |
| Publisher_xml | – name: Springer-Verlag – name: Springer – name: Springer Nature B.V |
| References | Russo, Bazan, Iacopetta, Kerr, Soussi, Gebbia (CR31) 2005; 23 Hagman, Larne, Edsjo, Bjartell, Ehrnstrom, Ulmert, Lilja, Ceder (CR24) 2010; 127 Gallardo, Navarro, Vinolas, Marrades, Diaz, Gel, Quera, Bandres, Garcia-Foncillas, Ramirez, Monzo (CR25) 2009; 30 Hermeking (CR10) 2010; 17 Jones, Baylin (CR14) 2007; 128 Raver-Shapira, Marciano, Meiri, Spector, Rosenfeld, Moskovits, Bentwich, Oren (CR6) 2007; 26 Cannell, Kong, Johnston, Chen, Collins, Dobbyn, Elia, Kress, Dickens, Clemens, Heery, Gaestel, Eilers, Willis, Bushell (CR29) 2010; 107 Corney, Hwang, Matoso, Vogt, Flesken-Nikitin, Godwin, Kamat, Sood, Ellenson, Hermeking, Nikitin (CR21) 2010; 16 Hermeking (CR2) 2007; 12 Tazawa, Tsuchiya, Izumiya, Nakagama (CR28) 2007; 104 Croce (CR3) 2009; 10 Li, Guessous, Zhang, Dipierro, Kefas, Johnson, Marcinkiewicz, Jiang, Yang, Schmittgen, Lopes, Schiff, Purow, Abounader (CR26) 2009; 69 Migliore, Petrelli, Ghiso, Corso, Capparuccia, Eramo, Comoglio, Giordano (CR23) 2008; 68 Wittekind, Bootz, Meyer (CR20) 2002 He, He, Lim, de Stanchina, Xuan, Liang, Xue, Zender, Magnus, Ridzon, Jackson, Linsley, Chen, Lowe, Cleary, Hannon (CR7) 2007; 447 Iacopetta (CR30) 2003; 21 Tarasov, Jung, Verdoodt, Lodygin, Epanchintsev, Menssen, Meister, Hermeking (CR4) 2007; 6 Laird (CR15) 2003; 3 Toyota, Suzuki, Sasaki, Maruyama, Imai, Shinomura, Tokino (CR12) 2008; 68 Christoffersen, Shalgi, Frankel, Leucci, Lees, Klausen, Pilpel, Nielsen, Oren, Lund (CR27) 2010; 17 Corney, Flesken-Nikitin, Godwin, Wang, Nikitin (CR9) 2007; 67 Welch, Chen, Stallings (CR11) 2007; 26 Halazonetis, Gorgoulis, Bartek (CR17) 2008; 319 Chim, Wong, Qi, Loong, Lam, Wong, Jin, Costello, Liang (CR34) 2010; 31 Herman, Graff, Myohanen, Nelkin, Baylin (CR19) 1996; 93 Garzon, Calin, Croce (CR1) 2009; 60 Chang, Wentzel, Kent, Ramachandran, Mullendore, Lee, Feldmann, Yamakuchi, Ferlito, Lowenstein, Arking, Beer, Maitra, Mendell (CR5) 2007; 26 Hoff (CR32) 2005; 23 Wiggins, Ruffino, Kelnar, Omotola, Patrawala, Brown, Bader (CR35) 2010; 70 Bommer, Gerin, Feng, Kaczorowski, Kuick, Love, Zhai, Giordano, Qin, Moore, Macdougald, Cho, Fearon (CR8) 2007; 17 Jones, Baylin (CR13) 2002; 3 Lujambio, Calin, Villanueva, Ropero, Sanchez-Cespedes, Blanco, Montuenga, Rossi, Nicoloso, Faller, Gallagher, Eccles, Croce, Esteller (CR18) 2008; 105 Lodygin, Tarasov, Epanchintsev, Berking, Knyazeva, Korner, Knyazev, Diebold, Hermeking (CR16) 2008; 7 Li, Fu, Tie, Hu, Kong, Wu, Zheng (CR22) 2009; 275 Ji, Hao, Zhang, Tang, Yang, Li, Xiang, Desano, Bommer, Fan, Fearon, Lawrence, Xu (CR33) 2009; 4 V Tarasov (1030_CR4) 2007; 6 M Toyota (1030_CR12) 2008; 68 Q Ji (1030_CR33) 2009; 4 Z Hagman (1030_CR24) 2010; 127 H Hermeking (1030_CR10) 2010; 17 N Raver-Shapira (1030_CR6) 2007; 26 H Tazawa (1030_CR28) 2007; 104 TD Halazonetis (1030_CR17) 2008; 319 PA Jones (1030_CR14) 2007; 128 A Russo (1030_CR31) 2005; 23 DC Corney (1030_CR21) 2010; 16 R Garzon (1030_CR1) 2009; 60 H Hermeking (1030_CR2) 2007; 12 GT Bommer (1030_CR8) 2007; 17 C Migliore (1030_CR23) 2008; 68 TC Chang (1030_CR5) 2007; 26 A Lujambio (1030_CR18) 2008; 105 D Lodygin (1030_CR16) 2008; 7 E Gallardo (1030_CR25) 2009; 30 NR Christoffersen (1030_CR27) 2010; 17 CM Wittekind (1030_CR20) 2002 CS Chim (1030_CR34) 2010; 31 B Iacopetta (1030_CR30) 2003; 21 Y Li (1030_CR26) 2009; 69 IG Cannell (1030_CR29) 2010; 107 PW Laird (1030_CR15) 2003; 3 JG Herman (1030_CR19) 1996; 93 L He (1030_CR7) 2007; 447 N Li (1030_CR22) 2009; 275 JF Wiggins (1030_CR35) 2010; 70 DC Corney (1030_CR9) 2007; 67 PA Jones (1030_CR13) 2002; 3 C Welch (1030_CR11) 2007; 26 PM Hoff (1030_CR32) 2005; 23 CM Croce (1030_CR3) 2009; 10 17554199 - Cell Cycle. 2007 Jul 1;6(13):1586-93 12042769 - Nat Rev Genet. 2002 Jun;3(6):415-28 18323444 - Science. 2008 Mar 7;319(5868):1352-5 20212154 - Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5375-80 16172461 - J Clin Oncol. 2005 Oct 20;23(30):7518-28 17554337 - Nature. 2007 Jun 28;447(7148):1130-4 18768788 - Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13556-61 18519671 - Cancer Res. 2008 Jun 1;68(11):4123-32 17875987 - Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15472-7 17540599 - Mol Cell. 2007 Jun 8;26(5):745-52 17823410 - Cancer Res. 2007 Sep 15;67(18):8433-8 19763153 - Nat Rev Genet. 2009 Oct;10(10):704-14 12619112 - Hum Mutat. 2003 Mar;21(3):271-6 17996645 - Cancer Cell. 2007 Nov;12(5):414-8 19736307 - Carcinogenesis. 2009 Nov;30(11):1903-9 17540598 - Mol Cell. 2007 Jun 8;26(5):731-43 19696787 - Cell Death Differ. 2010 Feb;17(2):236-45 20570894 - Cancer Res. 2010 Jul 15;70(14):5923-30 19006648 - Cancer Lett. 2009 Mar 8;275(1):44-53 21351256 - Int J Cancer. 2010 Dec 15;127(12):2768-76 17297439 - Oncogene. 2007 Jul 26;26(34):5017-22 19630570 - Annu Rev Med. 2009;60:167-79 19773441 - Cancer Res. 2009 Oct 1;69(19):7569-76 12671664 - Nat Rev Cancer. 2003 Apr;3(4):253-66 17656095 - Curr Biol. 2007 Aug 7;17(15):1298-307 19714243 - PLoS One. 2009 Aug 28;4(8):e6816 20145172 - Clin Cancer Res. 2010 Feb 15;16(4):1119-28 19461653 - Cell Death Differ. 2010 Feb;17(2):193-9 18719384 - Cell Cycle. 2008 Aug 15;7(16):2591-600 8790415 - Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 16186590 - J Clin Oncol. 2005 Oct 20;23(30):7395-6 20118199 - Carcinogenesis. 2010 Apr;31(4):745-50 19074879 - Cancer Res. 2008 Dec 15;68(24):10128-36 17320506 - Cell. 2007 Feb 23;128(4):683-92 |
| References_xml | – volume: 319 start-page: 1352 issue: 5868 year: 2008 end-page: 1355 ident: CR17 article-title: An oncogene-induced DNA damage model for cancer development publication-title: Science doi: 10.1126/science.1140735 – volume: 127 start-page: 2768 issue: 12 year: 2010 end-page: 2776 ident: CR24 article-title: miR-34c is down regulated in prostate cancer and exerts tumor suppressive functions publication-title: Int J Cancer doi: 10.1002/ijc.25269 – volume: 60 start-page: 167 year: 2009 end-page: 179 ident: CR1 article-title: MicroRNAs in Cancer publication-title: Annu Rev Med doi: 10.1146/annurev.med.59.053006.104707 – volume: 3 start-page: 415 issue: 6 year: 2002 end-page: 428 ident: CR13 article-title: The fundamental role of epigenetic events in cancer publication-title: Nat Rev Genet – volume: 31 start-page: 745 issue: 4 year: 2010 end-page: 750 ident: CR34 article-title: Epigenetic inactivation of the miR-34a in hematological malignancies publication-title: Carcinogenesis doi: 10.1093/carcin/bgq033 – volume: 447 start-page: 1130 issue: 7148 year: 2007 end-page: 1134 ident: CR7 article-title: A microRNA component of the p53 tumour suppressor network publication-title: Nature doi: 10.1038/nature05939 – volume: 107 start-page: 5375 issue: 12 year: 2010 end-page: 5380 ident: CR29 article-title: p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0910015107 – volume: 17 start-page: 236 issue: 2 year: 2010 end-page: 245 ident: CR27 article-title: p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC publication-title: Cell Death Differ doi: 10.1038/cdd.2009.109 – volume: 23 start-page: 7518 issue: 30 year: 2005 end-page: 7528 ident: CR31 article-title: The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment publication-title: J Clin Oncol doi: 10.1200/JCO.2005.00.471 – volume: 105 start-page: 13556 issue: 36 year: 2008 end-page: 13561 ident: CR18 article-title: A microRNA DNA methylation signature for human cancer metastasis publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0803055105 – volume: 128 start-page: 683 issue: 4 year: 2007 end-page: 692 ident: CR14 article-title: The epigenomics of cancer publication-title: Cell doi: 10.1016/j.cell.2007.01.029 – volume: 68 start-page: 10128 issue: 24 year: 2008 end-page: 10136 ident: CR23 article-title: MicroRNAs impair MET-mediated invasive growth publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-2148 – volume: 26 start-page: 745 issue: 5 year: 2007 end-page: 752 ident: CR5 article-title: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis publication-title: Mol Cell doi: 10.1016/j.molcel.2007.05.010 – volume: 70 start-page: 5923 issue: 14 year: 2010 end-page: 5930 ident: CR35 article-title: Development of a lung cancer therapeutic based on the tumor suppressor MicroRNA-34 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-0655 – volume: 6 start-page: 1586 issue: 13 year: 2007 end-page: 1593 ident: CR4 article-title: Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest publication-title: Cell Cycle doi: 10.4161/cc.6.13.4436 – volume: 21 start-page: 271 issue: 3 year: 2003 end-page: 276 ident: CR30 article-title: TP53 mutation in colorectal cancer publication-title: Hum Mutat doi: 10.1002/humu.10175 – volume: 69 start-page: 7569 issue: 19 year: 2009 end-page: 7576 ident: CR26 article-title: MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-0529 – volume: 23 start-page: 7395 issue: 30 year: 2005 end-page: 7396 ident: CR32 article-title: Is there a role for routine p53 testing in colorectal cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.07.021 – volume: 16 start-page: 1119 issue: 4 year: 2010 end-page: 1128 ident: CR21 article-title: Frequent downregulation of miR-34 family in human ovarian cancers publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-2642 – volume: 275 start-page: 44 issue: 1 year: 2009 end-page: 53 ident: CR22 article-title: miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells publication-title: Cancer Lett doi: 10.1016/j.canlet.2008.09.035 – volume: 68 start-page: 4123 issue: 11 year: 2008 end-page: 4132 ident: CR12 article-title: Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-0325 – volume: 4 start-page: e6816 issue: 8 year: 2009 ident: CR33 article-title: MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells publication-title: PLoS ONE doi: 10.1371/journal.pone.0006816 – volume: 7 start-page: 2591 issue: 16 year: 2008 end-page: 2600 ident: CR16 article-title: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer publication-title: Cell Cycle doi: 10.4161/cc.7.16.6533 – volume: 26 start-page: 731 issue: 5 year: 2007 end-page: 743 ident: CR6 article-title: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis publication-title: Mol Cell doi: 10.1016/j.molcel.2007.05.017 – volume: 10 start-page: 704 issue: 10 year: 2009 end-page: 714 ident: CR3 article-title: Causes and consequences of microRNA dysregulation in cancer publication-title: Nat Rev Genet doi: 10.1038/nrg2634 – volume: 67 start-page: 8433 issue: 18 year: 2007 end-page: 8438 ident: CR9 article-title: MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-1585 – volume: 17 start-page: 193 issue: 2 year: 2010 end-page: 199 ident: CR10 article-title: The miR-34 family in cancer and apoptosis publication-title: Cell Death Differ doi: 10.1038/cdd.2009.56 – volume: 104 start-page: 15472 issue: 39 year: 2007 end-page: 15477 ident: CR28 article-title: Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0707351104 – volume: 17 start-page: 1298 issue: 15 year: 2007 end-page: 1307 ident: CR8 article-title: p53-mediated activation of miRNA34 candidate tumor-suppressor genes publication-title: Curr Biol doi: 10.1016/j.cub.2007.06.068 – volume: 26 start-page: 5017 issue: 34 year: 2007 end-page: 5022 ident: CR11 article-title: MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells publication-title: Oncogene doi: 10.1038/sj.onc.1210293 – volume: 93 start-page: 9821 issue: 18 year: 1996 end-page: 9826 ident: CR19 article-title: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.93.18.9821 – volume: 30 start-page: 1903 issue: 11 year: 2009 end-page: 1909 ident: CR25 article-title: miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer publication-title: Carcinogenesis doi: 10.1093/carcin/bgp219 – year: 2002 ident: CR20 publication-title: TNM—Klassifikation maligner Tumoren. 6 edn. UICC International Union Against Cancer – volume: 3 start-page: 253 issue: 4 year: 2003 end-page: 266 ident: CR15 article-title: The power and the promise of DNA methylation markers publication-title: Nat Rev Cancer doi: 10.1038/nrc1045 – volume: 12 start-page: 414 issue: 5 year: 2007 end-page: 418 ident: CR2 article-title: p53 enters the microRNA world publication-title: Cancer Cell doi: 10.1016/j.ccr.2007.10.028 – volume: 319 start-page: 1352 issue: 5868 year: 2008 ident: 1030_CR17 publication-title: Science doi: 10.1126/science.1140735 – volume: 23 start-page: 7395 issue: 30 year: 2005 ident: 1030_CR32 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.07.021 – volume: 104 start-page: 15472 issue: 39 year: 2007 ident: 1030_CR28 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0707351104 – volume: 10 start-page: 704 issue: 10 year: 2009 ident: 1030_CR3 publication-title: Nat Rev Genet doi: 10.1038/nrg2634 – volume: 3 start-page: 253 issue: 4 year: 2003 ident: 1030_CR15 publication-title: Nat Rev Cancer doi: 10.1038/nrc1045 – volume: 26 start-page: 5017 issue: 34 year: 2007 ident: 1030_CR11 publication-title: Oncogene doi: 10.1038/sj.onc.1210293 – volume: 128 start-page: 683 issue: 4 year: 2007 ident: 1030_CR14 publication-title: Cell doi: 10.1016/j.cell.2007.01.029 – volume: 26 start-page: 731 issue: 5 year: 2007 ident: 1030_CR6 publication-title: Mol Cell doi: 10.1016/j.molcel.2007.05.017 – volume: 68 start-page: 4123 issue: 11 year: 2008 ident: 1030_CR12 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-0325 – volume: 68 start-page: 10128 issue: 24 year: 2008 ident: 1030_CR23 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-2148 – volume: 17 start-page: 236 issue: 2 year: 2010 ident: 1030_CR27 publication-title: Cell Death Differ doi: 10.1038/cdd.2009.109 – volume: 4 start-page: e6816 issue: 8 year: 2009 ident: 1030_CR33 publication-title: PLoS ONE doi: 10.1371/journal.pone.0006816 – volume: 93 start-page: 9821 issue: 18 year: 1996 ident: 1030_CR19 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.93.18.9821 – volume-title: TNM—Klassifikation maligner Tumoren. 6 edn. UICC International Union Against Cancer year: 2002 ident: 1030_CR20 – volume: 3 start-page: 415 issue: 6 year: 2002 ident: 1030_CR13 publication-title: Nat Rev Genet doi: 10.1038/nrg816 – volume: 447 start-page: 1130 issue: 7148 year: 2007 ident: 1030_CR7 publication-title: Nature doi: 10.1038/nature05939 – volume: 26 start-page: 745 issue: 5 year: 2007 ident: 1030_CR5 publication-title: Mol Cell doi: 10.1016/j.molcel.2007.05.010 – volume: 30 start-page: 1903 issue: 11 year: 2009 ident: 1030_CR25 publication-title: Carcinogenesis doi: 10.1093/carcin/bgp219 – volume: 69 start-page: 7569 issue: 19 year: 2009 ident: 1030_CR26 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-0529 – volume: 7 start-page: 2591 issue: 16 year: 2008 ident: 1030_CR16 publication-title: Cell Cycle doi: 10.4161/cc.7.16.6533 – volume: 107 start-page: 5375 issue: 12 year: 2010 ident: 1030_CR29 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0910015107 – volume: 275 start-page: 44 issue: 1 year: 2009 ident: 1030_CR22 publication-title: Cancer Lett doi: 10.1016/j.canlet.2008.09.035 – volume: 105 start-page: 13556 issue: 36 year: 2008 ident: 1030_CR18 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0803055105 – volume: 127 start-page: 2768 issue: 12 year: 2010 ident: 1030_CR24 publication-title: Int J Cancer doi: 10.1002/ijc.25269 – volume: 60 start-page: 167 year: 2009 ident: 1030_CR1 publication-title: Annu Rev Med doi: 10.1146/annurev.med.59.053006.104707 – volume: 67 start-page: 8433 issue: 18 year: 2007 ident: 1030_CR9 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-1585 – volume: 17 start-page: 193 issue: 2 year: 2010 ident: 1030_CR10 publication-title: Cell Death Differ doi: 10.1038/cdd.2009.56 – volume: 16 start-page: 1119 issue: 4 year: 2010 ident: 1030_CR21 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-2642 – volume: 6 start-page: 1586 issue: 13 year: 2007 ident: 1030_CR4 publication-title: Cell Cycle doi: 10.4161/cc.6.13.4436 – volume: 17 start-page: 1298 issue: 15 year: 2007 ident: 1030_CR8 publication-title: Curr Biol doi: 10.1016/j.cub.2007.06.068 – volume: 21 start-page: 271 issue: 3 year: 2003 ident: 1030_CR30 publication-title: Hum Mutat doi: 10.1002/humu.10175 – volume: 31 start-page: 745 issue: 4 year: 2010 ident: 1030_CR34 publication-title: Carcinogenesis doi: 10.1093/carcin/bgq033 – volume: 70 start-page: 5923 issue: 14 year: 2010 ident: 1030_CR35 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-0655 – volume: 12 start-page: 414 issue: 5 year: 2007 ident: 1030_CR2 publication-title: Cancer Cell doi: 10.1016/j.ccr.2007.10.028 – volume: 23 start-page: 7518 issue: 30 year: 2005 ident: 1030_CR31 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.00.471 – reference: 12042769 - Nat Rev Genet. 2002 Jun;3(6):415-28 – reference: 17320506 - Cell. 2007 Feb 23;128(4):683-92 – reference: 16186590 - J Clin Oncol. 2005 Oct 20;23(30):7395-6 – reference: 17297439 - Oncogene. 2007 Jul 26;26(34):5017-22 – reference: 19773441 - Cancer Res. 2009 Oct 1;69(19):7569-76 – reference: 12619112 - Hum Mutat. 2003 Mar;21(3):271-6 – reference: 18323444 - Science. 2008 Mar 7;319(5868):1352-5 – reference: 17540598 - Mol Cell. 2007 Jun 8;26(5):731-43 – reference: 19763153 - Nat Rev Genet. 2009 Oct;10(10):704-14 – reference: 17875987 - Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15472-7 – reference: 18768788 - Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13556-61 – reference: 18519671 - Cancer Res. 2008 Jun 1;68(11):4123-32 – reference: 19714243 - PLoS One. 2009 Aug 28;4(8):e6816 – reference: 20212154 - Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5375-80 – reference: 17996645 - Cancer Cell. 2007 Nov;12(5):414-8 – reference: 19696787 - Cell Death Differ. 2010 Feb;17(2):236-45 – reference: 17823410 - Cancer Res. 2007 Sep 15;67(18):8433-8 – reference: 8790415 - Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 – reference: 17540599 - Mol Cell. 2007 Jun 8;26(5):745-52 – reference: 19006648 - Cancer Lett. 2009 Mar 8;275(1):44-53 – reference: 19630570 - Annu Rev Med. 2009;60:167-79 – reference: 20145172 - Clin Cancer Res. 2010 Feb 15;16(4):1119-28 – reference: 20570894 - Cancer Res. 2010 Jul 15;70(14):5923-30 – reference: 17554199 - Cell Cycle. 2007 Jul 1;6(13):1586-93 – reference: 18719384 - Cell Cycle. 2008 Aug 15;7(16):2591-600 – reference: 17656095 - Curr Biol. 2007 Aug 7;17(15):1298-307 – reference: 19074879 - Cancer Res. 2008 Dec 15;68(24):10128-36 – reference: 20118199 - Carcinogenesis. 2010 Apr;31(4):745-50 – reference: 19461653 - Cell Death Differ. 2010 Feb;17(2):193-9 – reference: 21351256 - Int J Cancer. 2010 Dec 15;127(12):2768-76 – reference: 16172461 - J Clin Oncol. 2005 Oct 20;23(30):7518-28 – reference: 12671664 - Nat Rev Cancer. 2003 Apr;3(4):253-66 – reference: 17554337 - Nature. 2007 Jun 28;447(7148):1130-4 – reference: 19736307 - Carcinogenesis. 2009 Nov;30(11):1903-9 |
| SSID | ssj0021816 |
| Score | 2.4614704 |
| Snippet | The microRNA encoding genes
miR-34a
and
miR-34b/c
represent direct p53 target genes and possess tumor suppressive properties as they mediate apoptosis, cell... The microRNA encoding genes miR-34a and miR-34b/c represent direct p53 target genes and possess tumor suppressive properties as they mediate apoptosis, cell... |
| SourceID | proquest pubmed pascalfrancis crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 313 |
| SubjectTerms | Apoptosis Biological and medical sciences Breast Neoplasms - genetics Cell Line, Tumor Colorectal carcinoma Colorectal Neoplasms - genetics CpG Islands - genetics DNA Methylation DNA, Neoplasm - genetics Female Female genital diseases Gene Expression Regulation, Neoplastic Gene Silencing Genome Gynecology. Andrology. Obstetrics Humans Immunoenzyme Techniques Inactivation Investigative techniques, diagnostic techniques (general aspects) Kidney Neoplasms - genetics Kidneys Male Medical sciences Medicine Medicine & Public Health Methylation MicroRNAs - genetics Mutation Nephrology. Urinary tract diseases Original Article Ovarian cancer Ovarian Neoplasms - genetics Pancreatic cancer Pancreatic Neoplasms - genetics Pathology Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Prostate cancer Sarcoma Sarcoma - genetics Sarcoma - pathology Soft Tissue Neoplasms - genetics Soft Tissue Neoplasms - pathology Tumors Tumors of the urinary system Urologic Neoplasms - genetics |
| SummonAdditionalLinks | – databaseName: SpringerLink Contemporary (1997 - Present) dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3ZatwwULRpKYHSO6mbNkyhT-2Kei1Zlh5LyLYPbSjpQd6MLFuwsPEu9m4gn5a_64x8hJCk0L7ZzOiwNNLMeC7G3qnM4dqXBdepkVwW2uOZ85ZrUTiRyqRwOgQKf82OjvTJifnex3G3g7f7YJIMN_UY7BbEex68CZAyeXqX3UNup6lew_GP36OWhSwrGCiNTLlC7jiYMm_q4gozeriyLa6L7wpa3CRxXrOWBiY0e_xf03_CHvUyJ3zqiOQpu1PVz9iDb71V_Tm7mDXBoXoNqBxjb3OqLAzzmmIeuj-2sPRwOj_mQlqwddk_Fx8dFOdwsPoMVIj6vHOrw4ZAqbDpKrWLCeB100mmbgKnNoTKTWB5hjq6rSewaSgEbDEnTOq5qWiqZE4AR2WOavJfCpAWGQasA51AiyACvGC_Zoc_D77wvqQDd6harbnzhU2ckZVJnXNepS4pVGpR50pQVnG-zKw1maCAWG2VRWBZqiQzTqOcmDkpdthWvayrlwyM8MJ6q3GfC6mTSkujs0plfqpQjY1VxOJhb3PX5zunshuLfMzUHLYkj8O7iPM0Yu_HJqsu2cffkPevEMzYgorNo8qCE9gbKCjvL4Y2R-kIZc6pMhF7O0LxRNO62rpablpSxkgsjlMcAm7B0ZRQWIipjNhuR5uXw08TSnCQROzDQIiXw9_6Na_-CXuPbXf_1skX7zXbWjeb6g27786QCpr9cB7_AI9wLtw priority: 102 providerName: Springer Nature |
| Title | Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas |
| URI | https://link.springer.com/article/10.1007/s00428-010-1030-5 https://www.ncbi.nlm.nih.gov/pubmed/21225432 https://www.proquest.com/docview/853505169 https://www.proquest.com/docview/1468352055 https://www.proquest.com/docview/853993314 |
| Volume | 458 |
| WOSCitedRecordID | wos000288679000007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1432-2307 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0021816 issn: 0945-6317 databaseCode: M7P dateStart: 20030101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1432-2307 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0021816 issn: 0945-6317 databaseCode: 7X7 dateStart: 20030101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1432-2307 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0021816 issn: 0945-6317 databaseCode: 7RV dateStart: 20030101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1432-2307 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0021816 issn: 0945-6317 databaseCode: BENPR dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Nature customDbUrl: eissn: 1432-2307 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0021816 issn: 0945-6317 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1db9Mw0IINISTE54AwqIzEE9RaGif-eEIwrfAAVVVg6lvkOLFUqUtK0k7aT-Pfced8TBNsL7xYic6OHfvsu_N9EfJWSAtzn2dMJTpmcaYc7DlnmOKZ5UkcZVZ5R-GvcjZTy6Wed7Y5TWdW2Z-J_qDOK4t35EdAVoBYT4T-sPnFMGkUKle7DBq3yf4EWWNAZ7k4HeQtIF5eVanjhAmgk71SM2xjiGJoZjRNADRnyRWydH9jGpgh16a2-Bfv-Zfe1JOj6cP__JFH5EHHh9KPLeI8JreK8gm5-63TtD8lv6e1N7LeUhCY4cMrzDZMVyX6QbS3uLRy9Gy1YDw21JR595wdWZpd0OPNZ4rJqS9aUztoSDE8Nh6vZj2mcAS13Kod0zPj3efGtDoHud2UY7qr0S1svcKa-OW6wKGiioFaTH1Uok2ThzRAROjW4w5tAISAA_JzevLj-Avr0jwwC-LWllmXmcjquNCJtdaJxEaZSAzIYRHwL9bl0hgtOTrJKiMMAPNcRFJbBbyjtDF_RvbKqixeEKq548YZBSuexSoqVKyVLIR0EwGibSgCEvarnNouBjqm4linQ_Rmjxhp6N95mCYBeTc02bQBQG6qPLqCOkMLTEAPYgwM4LBHirQ7LJp0wIiAvBmgsMtxXk1ZVLsGBTRklcMEuqDX1FEYZJjzSRyQ5y2WXnY_iTDoQRSQ9z3aXnZ_7d-8vHGwh-Ree7-O9nivyN623hWvyR17Dqtej_xOxHIpfalGZP_TyWy-GKF17RzKxffTP5cmPrg |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3bbtMw9GgMxJAQ90EZDCPBCzRaajuJ_YAQGpRN6yqEhtS34DiJVKlLStMO9aP4AP6Oc5yk1QTb2x54S3Ts2HHONecG8CqMLJ59mngq0NKTicqR5nLjKZFYEUieWOUShQfRcKhGI_1lA361uTAUVtnyRMeo09LSP_I9FCsorHuhfj_94VHTKHKuth00aqw4ypY_0WKr3h1-xM_7mvP-p5P9A69pKuBZVO7nns0Tw62WmQ6stXkYWJ6EgUGtn6O0tHkaGaMjQSmZyoQGgWka8khbhZpKZKXA516D68jGI7L1otHavkNh6VyjWgZeiHK5daL6dc1SKgVNoRBIVl5wTgzenpoKv0het9L4l677l5_Wib_-3f_s4O7BnUbPZh9qwrgPG1nxAG4eN5EED-F3f-aCyOfMlgW-yJi6KbNxQXke9V9qVubsdPzVE9IwU6TNdbJnWbJk-9PPjJpvL-tQQpzIqPw3iQ8z6TJksbU2brvs1Lj0wC4rzwxSe9FlixmlvU3GNJKePMtoq-RCYZZaOxUUs-UgFQpJNne0wSoEEeARfLuSg9uGzaIssifAtMiFyY1CDEuk4pmSWkVZGOW9EE13P-yA32JVbJsa79RqZBKvqlM7RIx9dy_8OOjAm9WUaV3g5LLBu-dQdTWDCy3RTMMN7LRIGDfMsIpXGNiBlysocjE6V1Nk5aIiA5RMAT_AJdgFYxQVURaiJzvwuKaK9fI9TkUdeAfetmSyXv7Ct3l66WZfwNbByfEgHhwOj3bgVu1LoNjDZ7A5ny2y53DDniEGzHYdF2Dw_aqp5w_PdJaT |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3bbtMw9Gh0aEJCjDtlMIwEL9Coqe0k9gNCY1th2qiqiUl7C46TSJW6pDTtUD9tf8c5uU0TbG974C3RsWPHOdecG8A7P7B49nHkKE9LR0YqRZpLjaNEZIUneWRVmSh8FIxG6vRUj9fgosmFobDKhieWjDrOLf0j76NYQWE98HU_raMixnvDz7NfDjWQIkdr002jwpDDZPUbrbfi08Eefur3nA_3f-x-c-oGA45FRX_h2DQy3GqZaM9am_qe5ZHvGbQAOEpOm8aBMToQlJ6pjG8QGMc-D7RVqLUEVgp87h1YD1DHkB1Y_7I_Gh-31h6KztJRqqXn-CilG5eqW1UwpcLQFBiBROZ4V4Ti_Zkp8PukVWONf2m-f3ltS2E43PyPj_EhPKg1cLZTkcwjWEuyx7DxvY4xeAIXw3kZXr5gNs_wpSbUZ5lNMsoAqf5fszxlZ5NjR0jDTBbX11HfsmjFdmdfGbXlXlVBhjiRUWFwEixm2mPIfCs93fbYmSkTB3ssPzfIB7IeW84pIW46oZH05HlCWyXnCrPU9CmjaK4SUqD4ZIuSaliBIAI8hZNbObhn0MnyLHkBTItUmNQoxLZIKp4oqVWQ-EE68NGod_0uuA2Ghbau_k5NSKZhW7e6RMrQLe-FG3pd-NBOmVWlT24avH0FbdsZXGiJBhxuYKtByLBmk0XYYmMX3rZQ5G90riZL8mVBpikZCa6HS7BrxigqryzEQHbheUUhl8sPOJV74F342JDM5fLXvs3LGzf7BjaQaMKjg9HhFtyrnAwUlPgKOov5MnkNd-05IsB8u2YJDH7eNvn8AeS-oLM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Frequent+concomitant+inactivation+of+miR-34a+and+miR-34b%2Fc+by+CpG+methylation+in+colorectal%2C+pancreatic%2C+mammary%2C+ovarian%2C+urothelial%2C+and+renal+cell+carcinomas+and+soft+tissue+sarcomas&rft.jtitle=Virchows+Archiv+%3A+an+international+journal+of+pathology&rft.au=Vogt%2C+Markus&rft.au=Munding%2C+Johanna&rft.au=Gr%C3%BCner%2C+Martha&rft.au=Liffers%2C+Sven-thorsten&rft.date=2011-03-01&rft.pub=Springer+Nature+B.V&rft.issn=0945-6317&rft.eissn=1432-2307&rft.volume=458&rft.issue=3&rft.spage=313&rft_id=info:doi/10.1007%2Fs00428-010-1030-5&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=2274987111 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0945-6317&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0945-6317&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0945-6317&client=summon |